朝聚眼科(2219.HK)上市第二日續漲逾17% 市值超110億港元
格隆匯7月8日丨繼昨日首日上市收漲33%後,朝聚眼科今日盤中再度大漲超23%,創上市新高價17.4港元,最終收漲17.3%報16.54港元,市值114億港元。朝聚眼科是中國華北地區領先、全國知名的眼科醫療服務集團。根據弗若斯特沙利文報吿,於民營眼科醫院中,按2020年收益總額計,朝聚眼科於內蒙古排名第一,在華北地區排名第二,在中國排名第五。公司收入主要來自消費眼科服務及基礎眼科服務。招股書顯示,2018-2020年營收分別為6.33億元、7.15億元、7.94億元;同期利潤分別為2920萬元、7080萬元、1.2億元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.